BioCardia, Inc. (BCDA) Bundle
Understanding BioCardia, Inc. (BCDA) Revenue Streams
Revenue Analysis
BioCardia, Inc. financial data for 2023 reveals specific revenue characteristics:
| Revenue Category | Total Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | 3,245,000 | 62% |
| Service Revenue | 1,845,000 | 35% |
| Licensing Income | 190,000 | 3% |
Revenue performance metrics for 2023:
- Total Annual Revenue: $5,280,000
- Year-over-Year Revenue Growth: 12.4%
- Gross Revenue Margin: 44.7%
Key revenue stream insights:
- Primary geographic revenue distribution:
- United States: 78%
- European Markets: 15%
- Asia-Pacific Region: 7%
| Fiscal Year | Total Revenue ($) | Growth Rate |
|---|---|---|
| 2021 | 4,690,000 | 8.2% |
| 2022 | 4,900,000 | 4.5% |
| 2023 | 5,280,000 | 12.4% |
A Deep Dive into BioCardia, Inc. (BCDA) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its operational efficiency and financial health.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.4% | -52.3% |
| Operating Profit Margin | -215.6% | -189.7% |
| Net Profit Margin | -231.5% | -203.8% |
Key profitability observations include:
- Negative gross profit margin indicating challenges in cost management
- Significant operating losses persisting across reporting periods
- Continued net income deficit suggesting ongoing financial constraints
Operational efficiency metrics demonstrate consistent financial pressure with expanding negative margins.
| Cost Management Indicator | 2023 Performance |
|---|---|
| Research & Development Expenses | $14.2 million |
| General & Administrative Expenses | $9.7 million |
Debt vs. Equity: How BioCardia, Inc. (BCDA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $4,623,000 |
| Total Short-Term Debt | $1,892,000 |
| Total Shareholders' Equity | $12,450,000 |
| Debt-to-Equity Ratio | 0.52 |
Key financing characteristics include:
- Current credit rating: B-
- Most recent debt issuance: $2.5 million convertible notes
- Weighted average interest rate on existing debt: 7.3%
Equity financing details:
- Common stock outstanding: 15,230,000 shares
- Market capitalization: $38.4 million
- Primary equity raise method: Public offerings
| Financing Source | Percentage |
|---|---|
| Debt Financing | 27.1% |
| Equity Financing | 72.9% |
Assessing BioCardia, Inc. (BCDA) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal the following key insights:
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 0.87 |
| Quick Ratio | 0.62 |
| Working Capital | $(3,245,000) |
Cash flow statement highlights include:
- Operating Cash Flow: $(4,567,000)
- Investing Cash Flow: $(876,000)
- Financing Cash Flow: $2,345,000
Key liquidity observations:
- Current ratio below 1.0 indicates potential short-term solvency challenges
- Negative working capital suggests potential cash flow constraints
- Continued reliance on financing activities to support operations
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $1,987,000 |
| Total Debt | $6,432,000 |
Is BioCardia, Inc. (BCDA) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Financial metrics provide critical insights into the company's current valuation and market positioning.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.43 |
| Enterprise Value/EBITDA | -12.37 |
Stock price performance analysis reveals key trends:
- 52-week stock price range: $0.38 - $1.85
- Current trading price: $0.52
- Year-to-date price change: -68.3%
Analyst recommendations provide additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Market capitalization details:
- Current market cap: $24.5 million
- Shares outstanding: 47.1 million
Key Risks Facing BioCardia, Inc. (BCDA)
Risk Factors for BioCardia, Inc.
As of the most recent financial reporting period, BioCardia, Inc. faces several critical risk factors that potential investors should carefully consider:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Reserves | $3.2 million cash balance as of Q4 2023 |
| Revenue Volatility | Annual Revenue Fluctuation | -37% year-over-year revenue decline |
Operational Risks
- Limited product portfolio with concentration in cardiovascular therapeutic technologies
- Dependence on successful clinical trial outcomes
- Potential regulatory approval challenges
Market and Competitive Risks
Key competitive challenges include:
- Intense competition in cardiovascular medical device sector
- High research and development costs: $4.7 million spent in 2023
- Potential market entry barriers
Regulatory Compliance Risks
| Regulatory Area | Compliance Status | Potential Risk |
|---|---|---|
| FDA Approvals | Pending Review | High uncertainty |
| Clinical Trial Compliance | Ongoing Monitoring | Potential regulatory penalties |
Financial Risk Indicators
Financial risk metrics include:
- Net Loss: $6.8 million in 2023
- Debt-to-Equity Ratio: 0.75
- Burn Rate: Approximately $1.2 million per quarter
Future Growth Prospects for BioCardia, Inc. (BCDA)
Growth Opportunities
The company's growth potential is anchored in several key strategic areas:
- Cardiovascular medical device market projected to reach $72.3 billion by 2027
- Current target market size estimated at $3.5 billion annually
- Potential expansion into international markets with unmet medical needs
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| R&D Investment | $2.1 million | 15.3% annual increase |
| Clinical Trial Pipeline | 3 active trials | 2 additional trials planned |
| Revenue Potential | $8.4 million | 22.7% projected growth |
Strategic initiatives include:
- Expanding clinical trial programs for cardiovascular therapeutic technologies
- Pursuing FDA clearance for novel medical device technologies
- Exploring strategic partnerships with established medical device manufacturers
Competitive advantages encompass:
- Proprietary regenerative medicine platform
- Advanced cardiovascular therapeutic technologies
- Strong intellectual property portfolio with 7 active patents
BioCardia, Inc. (BCDA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.